Introducing minimal residual disease in acute myeloid leukemia
1aDepartment of Hematology and Bone Marrow Transplantation, Rambam Healthcare Campus, Haifa bDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem cBruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Purpose Of Review:
Acute myeloid leukemia (AML) is a heterogeneous disease. Detection of minimal residual disease (MRD) has the potential to improve risk stratification, and its routine monitoring may allow timely therapeutic actions such as allogeneic hematopoietic stem cell transplantation. The current review will discuss challenges and available evidence for clinical application of MRD detection in AML management.
Recent Findings:
The heterogeneous nature of AML, variations in genetic aberrations and immunophenotypes among patients and between malignant subclones coexisting within a single patient, is a challenge for the development of a reliable MRD test in AML. MRD value was demonstrated in subtypes of AML in which reliable leukemia-specific genetic marker is present (e.g., core-binding leukemia, AML positive for NPM1 mutation). Multicolor flow cytometry and quantitative PCR monitoring for Wilms tumor 1 gene transcript have also been shown to correlate with disease progression. MRD results should always be interpreted within patient-specific clinical context considering other risk factors and timing of MRD eradication.
Summary:
Introduction of MRD testing into routine clinical practice is a challenge in AML. An improvement in laboratory techniques along with identification of additional leukemia-specific markers is required.
Insights
Minimal residual disease (MRD) detection in acute myeloid leukemia (AML) offers improved risk stratification and timely treatment adjustments. However, challenges in AML heterogeneity and marker identification hinder routine clinical application of MRD testing.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Acute myeloid leukemia (AML) is a complex and heterogeneous malignancy.
- Minimal residual disease (MRD) detection is crucial for risk stratification and guiding therapy in AML.
- Current challenges exist in developing reliable MRD detection methods for routine clinical use.
Purpose of the Study:
- To review the challenges and evidence for clinical application of MRD detection in AML management.
- To explore the potential of MRD monitoring for improving patient outcomes and therapeutic decisions.
- To discuss the current state and future directions for MRD testing in AML.
Main Methods:
- Review of existing literature on MRD detection techniques in AML.
- Analysis of current evidence supporting the clinical utility of MRD monitoring.
- Discussion of challenges related to AML heterogeneity and marker identification.
Main Results:
- AML heterogeneity poses a significant challenge for developing standardized MRD tests.
- MRD detection shows promise in AML subtypes with specific genetic markers (e.g., core-binding leukemia, NPM1 mutation).
- Techniques like multicolor flow cytometry and qRT-PCR for WT1 correlate with disease progression.
Conclusions:
- Routine implementation of MRD testing in AML faces significant hurdles.
- Advancements in laboratory techniques and identification of novel leukemia-specific markers are necessary.
- Further research is required to overcome current limitations and optimize MRD-guided therapy in AML.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025